Role of grape seed polyphenols in Alzheimer’s disease neuropathology

References

• Alzheimer’s Association. 2008 Alzheimer’s Disease Facts and Figures. AlzheimersDement. 2008;4:110–133.
   PubMed Web of Science ®Google Scholar
• Cummings JL. Treatment of Alzheimer’s disease: Current and future therapeutic approaches. Rev Neurol Dis. 2004;1:60–69.
   PubMedGoogle Scholar
• Sano M. Current concepts in the prevention of Alzheimer’s disease. CNSSpectr. 2003;8:846–853.
   Google Scholar
• Religa D, Winblad B. Therapeutic strategies for Alzheimer’s disease based on new molecular mechanisms. Acta NeurobiolExp. 2003;63(4): 393–396.
   Web of Science ®Google Scholar
• Pangalos MN, Jacobsen SJ, Reinhart PH. Disease modifying strategies for the treatment of Alzheimer’s disease targeted at modulating levels of beta-amyloid peptide. Biochem Soc Trans. 2005;33(Pt 4):553–558.
   Google Scholar
• Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer’s disease. Acta Neuropathol. 2009;11:5–36.
   Google Scholar
• Davies P, Koppel J. Mechanism-based treatment for Alzheimer’s disease. Dialogues Clin Neurosci. 2009;11:159–169.
   PubMedGoogle Scholar
• Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer’s disease-causing mutations by augmenting Ap42 production. Nat Med. 2005;11:545–550.
   PubMed Web of Science ®Google Scholar
• Golde TE, Eckman CB, Younkin SG. Biochemical detection of Ap isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochim Biophys Acta. 2000;1502:172–187.
   PubMed Web of Science ®Google Scholar
• Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer‘s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer‘s disease. Nat Med. 1996;2:864–870.
   PubMed Web of Science ®Google Scholar
• Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713.
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79–84.
   PubMed Web of Science ®Google Scholar
• Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082): 352–357.
   PubMed Web of Science ®Google Scholar
• Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103:5161–5166.
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–539.
   PubMed Web of Science ®Google Scholar
• Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556–561.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002; 297(5580):353–356.
   PubMed Web of Science ®Google Scholar
• Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Ann N Y Acad Sci. 1996;77:121–131.
   Google Scholar
• Sahara N, Maeda S, Takashima A. Tau oligomerization: A role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res. 2008;5:591–598.
   PubMed Web of Science ®Google Scholar
• Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476–481.
   PubMed Web of Science ®Google Scholar
• Berger Z, Roder H, Hanna A, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci. 2007;27:3650–3652.
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Bonavita V Neurodegeneration and Alzheimer’s disease: The lesson from tauopathies. Neurol Sci. 2007;28:63–71.
   PubMed Web of Science ®Google Scholar
• Ono K, Condron MM, Ho L, et al. Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cyotoxicity. J Biol Chem. 2008;283:32176–32187.
   PubMed Web of Science ®Google Scholar
• Ho L, Yemul S, Wang J, Pasinetti GM. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J Alzheimers Dis. 2009;16:433–439.
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao W, et al. Grape-derived polyphenolics prevent abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s disease. J Neurosci. 2008;28:6388–6392.
   PubMed Web of Science ®Google Scholar
• Song X, Siriwardhana N, Rathore K, Lin D, Wang HC. Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitorsamino)-1-(3-pyridyl)-1- butanone and benzo[a]pyrene. Mol Carcinog. 2010;49:450–63.
   PubMed Web of Science ®Google Scholar
• Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009;58:1743–1746.
   PubMed Web of Science ®Google Scholar
• Montagut G, Onnockx S, Vaque M, et al. Oligomers of a grape-seed procyanidin extract activate the insulin receptor and key targets of the insulin signaling pathway differently from insulin. J Nutr Biochem. 2010;2:476–481.
   Google Scholar
• Karaaslan O, Ulusoy MG, Kankaya Y, et al. Protective effect of grape seed extract against ischaemia/reperfusion injury in a rat epigastic flap model. J Plast Reconstr Aesthet Surg. 2010;63:705–710.
   PubMed Web of Science ®Google Scholar
• Khanna S, Venojarvi M, Roy S, et al. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic Biol Med. 2002;33:1089–1096.
   PubMed Web of Science ®Google Scholar
• Li X, Xhao Y, Gao H, et al. Grape seed proanthocyanidins ameliorate diabetic nephropathy via modulation of levels of AGE, RAGE and CTGH. Nephron Exp Nephrol. 2009;111:e31–e41.
   PubMed Web of Science ®Google Scholar
• Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed proanthocyanidin extract: Importance in human health and disease prevention. Toxicology. 2000;148:187–197.
   PubMed Web of Science ®Google Scholar
• Montagut G, Blade C, Blay M, et al. Effects of a grape seed procyanidin extract (GSPE) on insulin resistance. J Nutr Biochem. Dec 3, 2009. [Epub ahead of print].
   Web of Science ®Google Scholar
• Wang YJ, Thomas P, Zhong JH, et al. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer’s disease mouse. Neurotox Res. 2009;15:3–14.
   PubMed Web of Science ®Google Scholar
• Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol. 1999;299:152–178.
   Web of Science ®Google Scholar
• Ferruzzi MG, Lobo JK, Janle EM, et al. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: Implications for treatment in Alzheimer’s disease. J Alzheimers Dis. 2009;1:113–124.
   Google Scholar
• Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274: 99–103.
   PubMed Web of Science ®Google Scholar
• Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer’s disease brain and assembled in vitro are based on beta- structure in the core domain. Biochemistry. 2004;43:1694–1703.
   PubMed Web of Science ®Google Scholar
• Kajava AV Baxa U, Wickner RB, Steven AC. A model for Ure2p prion filaments and other amyloids: The parallel superpleated beta-structure. Proc Natl Acad Sci US A. 2004;101:7885–7890.
   PubMed Web of Science ®Google Scholar
• Lindwall G, Cole RD. The purification of tau protein and the occurrence of two phosphorylation states of tau in brain. J Biol Chem. 1984; 259:12241–12245.
   Web of Science ®Google Scholar
• Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem. 1994;269:24290–24297.
   PubMed Web of Science ®Google Scholar
• von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta. 2005;1739:158–166.
   PubMed Web of Science ®Google Scholar
• Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci USA. 2003;100:9034–9038.
   PubMed Web of Science ®Google Scholar
• Giannetti AM, Lindwall G, Chau MF, Radeke MJ, Feinstein SC, Kojlstaedt LA. Fibers of tau filaments, but not full length tau, exhibit a cross beta-structure: Implications for the formation of paired helical filaments. Protein Sci. 2000;9:2424–2435.
   Web of Science ®Google Scholar
• Sadqi M, Hernandez F, Pan U, et al. Alpha-helix structure in Alzheimer’s disease aggregates of tau-protein. Biochemistry. 2002;41:7150–7155.
   PubMed Web of Science ®Google Scholar
• Goux WJ, Kopplin L, Nguyen AD, et al. The formation of straight and twisted filaments from short tau peptides. J Biol Chem. 2004;279: 26868–26875.
   PubMed Web of Science ®Google Scholar
• Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food Chem Toxicol. 2002;40: 1731–1743.
   PubMed Web of Science ®Google Scholar